Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100
Aurobindo Pharma’s US business is expected to stage a marked improvement. A mix of factors, which includes a sturdy pipeline of new products, expected traction in the lucrative injectables space driven by strong new product pipeline and commissioning of a new facility coupled with growth in the recently launched products would boost US business’ sales
Aurobindo Pharma plans to launch around 50 products in the US in FY2021 and expects to sustain the launch momentum into FY2022E as well: Reuters